Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT) agreed to a confidential settlement of a lawsuit brought by Medtronic MiniMed accusing J&J’s Animas diabetes business of infringing patents, according to a regulatory filing.
MiniMed sued Animas in May 2012, alleging that the Animas OneTouch Ping glucose management system and the IR 1250, IR 2020 and IR 2000 insulin pumps infringe 9 MiniMed patents. Although MiniMed later withdrew 2 of the patents from the suit, is pressed ahead with the case on the remaining 7 patents, seeking injunctive relief and damages, according to the filing.
Last month the companies agreed to put the case to bed for unspecified terms; Judge Ronald Lew of the U.S. District Court for Central California dismissed the suit with prejudice July 31, according to court documents.
July was a busy month in the courts for the diabetes space. Another Johnson & Johnson subsidiary found itself in the legal crosshairs when UniStrip accused LifeScan of orchestrating a campaign to monopolize the market for test strips used with its blood glucose meters in early July; 2 other diabetes players, Dexcom (NSDQ:DXCM) and Abbott Diabetes Care (NYSE:ABT), settled “all pending patent infringement legal proceedings” brought by Abbott against DexCom July 7. And federal and state regulators agreed to a $2.8 million settlement with Medtronic to close the books on a lawsuit joined by 36 states and the federal government, spurred by whistleblower complaints that Medtronic was illegally soliciting Medicare and Medicaid patients to replace their insulin pumps.